PO.TB10.04 · 肿瘤生物学
受照射的ER阳性乳腺癌淋巴结的空间蛋白质谱分析提示淋巴结照射调节免疫功能
Spatial protein profiling of irradiated ER positive breast cancer lymph nodes suggests nodal irradiation modulates immune function
该海报暂无可下载的资料
AACR 官方页面
作者与单位 Authors & Affiliations
摘要 Abstract
中文摘要
背景:我们假设区域淋巴结照射(RNI)对乳腺癌的全身获益源于受累淋巴结中的免疫刺激。我们比较了在一项术前与术后常规分割(2 Gy/fx)与大分割(2.67 Gy/fx)RNI方案的前瞻性试验中接受治疗患者的受累淋巴结(ILN)(SAPHIRE NCT02912312)。
方法:对17例ER+、pN+乳腺癌患者的ILN使用免疫相关蛋白进行数字空间谱分析。6例术后病例未接受新辅助化疗(NACT)(未治疗对照)。其余所有病例均接受NACT +/- RNI。4例术前短程RNI(RNI_NACT-2.67Gy/fx);5例术前标准RNI(RNI_NACT-2 Gy/fx);3例NACT后术后RNI。选取5个感兴趣区域(ROI),并归类为“肿瘤”(PanCK+)或“免疫”(CD45+)区室。在选定病例中评估细胞密度与空间分析。对所有ROI中的蛋白表达进行Pearson相关性、T检验和KS检验,FDR<0.1,P值<0.05。对Log2差异介于-1和1之间的信号使用校正LMM分析患者层面的变异,并按区室对ROI进行PCA。
结果:最近邻分析显示,肿瘤细胞与免疫细胞之间的中位距离从未治疗、到NACT、再到NACT+RNI依次增加,而术前短程与标准RNI之间无差异。邻近性分析揭示,CD3+细胞相对于CK+细胞的分布随治疗强度增加而变化,更倾向于免疫细胞靠近的频率增加,尽管每个CK+细胞周围的平均细胞数随治疗强度增加而减少。CK+细胞密度保持稳定,提示为迁移而非细胞死亡。免疫ROI表达谱的差异提示术前短程中存在更多免疫信号传导。考虑所有放疗(RT),27个差异表达蛋白(DEP)在术后肿瘤ROI中显著上调,无一显著下调。经LMM校正后,11个标志物在术后病例中上调,无一下调。我们发现术前淋巴结中SMA、CD4、CD45RO、CD14、CD11c、TIM-3和B7-H3的表达较低。经LMM校正后,免疫ROI中无显著DEP残留。前两个主成分占总方差的45.8%,其中PC1主要根据术前RNI区分样本。术前短程与术前标准相比,术前短程中有9个蛋白升高、0个降低,包括CD27、Sting、CD40、CD11c、CD25。
结论:术前放疗促进免疫微环境重塑,在ILN中补充新辅助化疗的作用,且不改变免疫细胞密度。受照射ILN中不同的免疫信号提示RNI具有较低的免疫抑制表型,以及术前短程RNI中潜在的免疫激活。样本量小限制了结论,后续将开展免疫研究以优化放疗方案。
查看英文原文 English abstract
Background: We hypothesized that the systemic benefit of regional nodal irradiation (RNI) for breast cancer derives from immune stimulation in involved nodes. We compared involved lymph nodes (ILN) from patients treated on a prospective trial of pre-operative and post-operative conventional (2 Gy/fx) versus hypofractionated (2.67 Gy/fx) RNI regimens (SAPHIRE NCT02912312).
Methods: 17 patients ILNs with ER+, pN+ BC were Digitally Spatially Profiled with immune-related proteins. 6 post-op cases had no neoadjuvant chemotherapy (NACT) (untreated controls). All others had NACT +/- RNI. 4 pre-operative RNI short-course (RNI_NACT-2.67Gy/fx); 5 pre-op standard RNI (RNI_NACT-2 Gy/fx); 3 post-op RNI after NACT. 5 Regions of Interest (ROIs) were selected and categorized as “Tumor” (PanCK+) or “Immune” (CD45+) compartments. Cell density and spatial analysis were assessed in selected cases. Pearson's correlations, T-Test and KS tests were performed on protein expression in all ROIs, FDR < 0.1, P value < 0.05. Signals with Log2 differences between -1 and 1 were analyzed using adjusted LMM for patient-level variation, and PCA of ROIs by compartment was performed.
Results: Nearest neighbor analysis shows increasing median distance between tumor and immune cells from untreated, to NACT, and NACT+RNI, and no differences between short and standard pre-operative RNI. Proximity analysis reveals the distribution of CD3+ cells from the CK+ cells changes with increasing therapy, favoring frequency of closer immune cells, although the average number of cells around each CK+ cell diminishes with increasing therapies. CK+ cell density remains stable, suggesting migration rather than cell death. Differences in expression profiles of immune ROIs suggest more immune signaling in pre-op short. Considering all RT, 27 differentially expressed proteins (DEP) were significantly upregulated in Post tumor ROIs. None were significantly downregulated. After correction by LMM, 11 markers were up in Post cases and none downregulated. We found lower expression of SMA , CD4, CD45RO, CD14, CD11c, TIM-3, and B7-H3 in the Pre nodes. No significant DEPs remain in immune ROIs after LMM correction. The first two principal components accounted for 45.8% of the total variance, with PC1 largely separating samples based on Pre RNI. Pre-short vs Pre-standard showed 9 increased and 0 decreased proteins in Pre-short including CD27, Sting, CD40, CD11c, CD25.
Conclusions: Pre-operative radiation contributes to Immune microenvironment remodeling, complementing neoadjuvant chemotherapy in ILN, without altering immune cell density. Different immune signals in irradiated ILN suggest a less immunosuppressive phenotype in RNI, and potential immune activation in Pre-short RNI. Small sample size limits conclusions, immune studies will follow to optimize radiation regimens.
利益披露 Disclosure
S. O. Dudzinski, None..
E. N. Barrientos-Toro, None..
B. D. Smith, None..
S. Hernandez, None..
A. Serrano, None..
K. Khaja, None..
L. Kostousov, None..
W. Lu, None..
R. Zacharia, None..
N. Comeaux, None..
S. M. Luisa, None..
M. G. Raso, None..
J. Wang, None..
K. Hoffman, None..
W. A. Woodward, None.